SEI Investments’s Immunic IMUX Stock Holding History

SEI Investments’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-131	Closed	-$357K	–	3701
2018 Q1	$357K	Hold	131	–	–	﹤0.01%	1715
2017 Q4	$312K	Hold	131	–	–	﹤0.01%	1791
2017 Q3	$265K	Hold	131	–	–	﹤0.01%	1795
2017 Q2	$152K	Hold	131	–	–	﹤0.01%	1951
2017 Q1	$210K	Hold	131	–	–	﹤0.01%	1764
2016 Q4	$228K	Hold	131	–	–	﹤0.01%	1758
2016 Q3	$321K	Buy	+131	New	+$323K	﹤0.01%	1560

Other funds holding IMUX

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SEI Investments's IMUX Position: Q2 2018 in Review

SEI Investments sold out of Immunic (IMUX) in Q2 2018, closing a stake of 131 shares — an estimated $357K sold.

SEI Investments first reported a position in IMUX in Q3 2016 and held it in 7 quarters. The position peaked at $357K in Q1 2018. 62 funds tracked by Wall St. Rank hold IMUX as of Q2 2018.

SEI Investments reported no remaining Immunic position as of Q2 2018 after selling out during the quarter.
SEI Investments sold 131 Immunic shares in Q2 2018, an estimated $357K.
SEI Investments first reported a position in Immunic in Q3 2016 and held it in 7 quarters.
SEI Investments's Immunic position peaked at $357K in Q1 2018.
62 funds tracked by Wall St. Rank held Immunic as of Q2 2018.

Based on SEI Investments's 13F filing for Q2 2018, filed 3 Aug 2018.